Voss Capital LP Purchases 85,000 Shares of uniQure N.V. $QURE

Voss Capital LP grew its stake in shares of uniQure N.V. (NASDAQ:QURE) by 68.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 210,000 shares of the biotechnology company’s stock after buying an additional 85,000 shares during the quarter. Voss Capital LP’s holdings in uniQure were worth $5,025,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Vontobel Holding Ltd. bought a new position in shares of uniQure during the fourth quarter valued at about $286,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of uniQure during the fourth quarter valued at about $1,920,000. Wells Fargo & Company MN grew its stake in shares of uniQure by 547.8% during the fourth quarter. Wells Fargo & Company MN now owns 70,236 shares of the biotechnology company’s stock valued at $1,681,000 after buying an additional 59,393 shares during the last quarter. Rhenman & Partners Asset Management AB purchased a new stake in shares of uniQure during the fourth quarter worth about $1,899,000. Finally, Senvest Management LLC purchased a new stake in shares of uniQure during the fourth quarter worth about $1,196,000. 78.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $12.00 to $35.00 in a report on Wednesday, March 11th. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a report on Tuesday, May 5th. Chardan Capital raised their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Wolfe Research started coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

uniQure Price Performance

QURE stock opened at $27.57 on Friday. The firm has a 50 day moving average price of $22.52 and a 200-day moving average price of $21.80. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Insider Activity

In related news, Director Robert Gut sold 7,552 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $26.05, for a total transaction of $196,729.60. Following the completion of the sale, the director owned 27,435 shares of the company’s stock, valued at $714,681.75. This trade represents a 21.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 1,993 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the sale, the director directly owned 43,254 shares of the company’s stock, valued at $1,170,453.24. This trade represents a 4.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 85,817 shares of company stock valued at $2,232,383. 4.65% of the stock is currently owned by insiders.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.